Image by Muffet via Flickr
Talk about inflation...
In my last post, I wrote about Ampyra, an oral drug that was recently approved by the FDA to treat MS. This drug does nothing to treat the Multiple Sclerosis disease process itself, but is meant to increase muscle strength and mobility, and provide some symptom relief for MS sufferers. In trials, Ampyra helped 35% of test subjects taking it increase their walking speed by 25% (in timed 25 foot walks).
Ampyra is basically the same exact drug as a much older compound called 4-AP, in a time released form. 4-AP has been available for years from compounding pharmacies, and can be compounded in a time released capsule.
When purchased from a compounding pharmacy, 4-AP costs something around 30 bucks a month, if I remember correctly.
Now that the drug has been renamed, patented, and marketed by the pharmaceutical company Acorda Therapeutics, the wholesale price of Ampyra, which was announced today, will be $1056 for a 30 day supply, or little more than 1000 bucks a month more than good old 4-AP...
When I first read that price, my eyes nearly fell out.
Can I get a "Holy Shit"?...
UPDATE: received this comment from a reader who was in the Ampyra trials. Turns out I may be wrong about the drug being similar in effectiveness to 4-AP:
Fampridine (the name used for the drug while it was undergoing trials) is not the same as 4-AP SR, no matter how similar they sound. I was on the trial, and it works as least twice as well--my improvements in mobility, walking, balance, cognition, muscle strength, everything, were twice as good as the effects of 4-AP SR, which I have also used. Ampyra is worth it for me, no matter what the cost, which of course is huge, but I will try to afford the co-pay no matter what.
I certainly hope this reader is correct. A drug that effectively treats the range of MS symptoms reflected in the above comment will be quite welcome, indeed. As with all of the other MS drugs, I suspect it's effectiveness will vary widely from patient to patient...